TY  - JOUR
AU  - Bastos-Oreiro, Mariana
AU  - Gutierrez, Antonio
AU  - Reguera, Juan Luís
AU  - Iacoboni, Gloria
AU  - López-Corral, Lucía
AU  - Terol, María José
AU  - Ortíz-Maldonado, Valentín
AU  - Sanz, Jaime
AU  - Guerra-Dominguez, Luisa
AU  - Bailen, Rebeca
AU  - Mussetti, Alberto
AU  - Abrisqueta, Pau
AU  - Hernani, Rafael
AU  - Luzardo, Hugo
AU  - Sancho, Juan-Manuel
AU  - Delgado-Serrano, Javier
AU  - Salar, Antonio
AU  - Grande, Carlos
AU  - Bento, Leyre
AU  - González de Villambrosía, Sonia
AU  - García-Belmonte, Daniel
AU  - Sureda, Anna
AU  - Pérez-Martínez, Antonio
AU  - Barba, Pere
AU  - Kwon, Mi
AU  - Martín García-Sancho, Alejandro
PY  - 2022
DO  - 10.3389/fimmu.2022.855730
UR  - http://hdl.handle.net/10668/20580
T2  - Frontiers in immunology
AB  - Real-world evidence comparing the efficacy of chimeric antigen receptor (CAR) T-cell therapy against that of the previous standard of care (SOC) for refractory large B-cell lymphoma (LBCL) is scarce. We retrospectively collected data from patients...
LA  - en
KW  - CAR-T cell therapy
KW  - real world evidence (RWE)
KW  - refractory aggressive B cell lymphoma
KW  - scholar-1 criteria
KW  - standard of care (SOC)
KW  - Antigens, CD19
KW  - Humans
KW  - Lymphoma, Large B-Cell, Diffuse
KW  - Receptors, Chimeric Antigen
KW  - Retrospective Studies
KW  - T-Lymphocytes
TI  - Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups.
TY  - research article
VL  - 13
ER  -